Ocular therapeutix™ to participate in clinical trials at the summit (cts) 2025

Bedford, mass., june 16, 2025 (globe newswire) -- ocular therapeutix, inc. (nasdaq: ocul, “ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at clinical trials at the summit 2025, taking place on june 21, 2025, in las vegas, nv.
CTS Ratings Summary
CTS Quant Ranking